CN103446119B - Fluevirosines A在制备治疗急性肾衰药物中的应用 - Google Patents
Fluevirosines A在制备治疗急性肾衰药物中的应用 Download PDFInfo
- Publication number
- CN103446119B CN103446119B CN201310432836.4A CN201310432836A CN103446119B CN 103446119 B CN103446119 B CN 103446119B CN 201310432836 A CN201310432836 A CN 201310432836A CN 103446119 B CN103446119 B CN 103446119B
- Authority
- CN
- China
- Prior art keywords
- fluevirosines
- renal failure
- acute renal
- application
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000033626 Renal failure acute Diseases 0.000 title claims abstract description 32
- 201000011040 acute kidney failure Diseases 0.000 title claims abstract description 32
- 208000009304 Acute Kidney Injury Diseases 0.000 title claims abstract description 31
- 208000012998 acute renal failure Diseases 0.000 title claims abstract description 31
- 229930193033 fluevirosine Natural products 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 title abstract description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 12
- 229960000890 hydrocortisone Drugs 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 206010030302 Oliguria Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 201000003126 Anuria Diseases 0.000 description 3
- 240000007003 Flueggea virosa Species 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000008436 biogenesis Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 230000008327 renal blood flow Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及Fluevirosines A的新医药用途，即Fluevirosines A在制备治疗急性肾衰药物中的应用。于本发明涉及的Fluevirosines A在制备抗急性肾衰药物中的用途属于首次公开，由于骨架类型属于全新的骨架类型，而且其对于急性肾衰抑制活性强，具备突出的实质性特点，同时用于抗急性肾衰显然具有显著的进步。
Description
技术领域
本发明涉及化合物Fluevirosines A的新用途，尤其涉及Fluevirosines A在制备治疗急性肾衰药物中的应用。
背景技术
急性肾功能衰竭（Acute Renal Failure，ARF）是由多种原因引起的临床综合征，临床表现为急性少尿（尿量<400mLPd）或无尿（尿量<100mLPd），体内氮质代谢产物排出产生障碍，迅速出现氮质血症，并引起全身各系统相应功能失调。引起急性肾衰的主要因素是肾血流量的急剧减少，以及由于肾组织缺血引起的氧化应激和细胞损伤，最终导致肾脏组织结构的破坏和功能的恶化。目前临床上尚无公认的治疗急性肾衰有效的药物，仅能通过纠正水电解质平衡，纠正酸中毒等对症治疗措施改善症状，后期还需要通过血液透析维持机体机能。在改善肾脏血流灌注障碍和减轻肾组织损伤方面有明显疗效的临床药物少见。
本发明涉及的化合物Fluevirosines A是一个2013年发表（Hua Zhang，et al.,Fluevirosines A-C:A Biogenesis Inspired Example in the Discovery of New Bioactive Scaffolds from Flueggea virosa.Organic Letters，2013，15（1）：120–123.）的新化合物，该化合物拥有全新的骨架类型，目前的用途仅仅对白血病和肺癌细胞有一定的细胞毒性（Hua Zhang，et al.,Fluevirosines A-C:A Biogenesis Inspired Example in the Discovery of New Bioactive Scaffolds from Flueggea virosa.Organic Letters，2013，15（1）：120–123.），本发明涉及的Fluevirosines A在制备治疗急性肾衰药物中的用途属于首次公开。
发明内容
本发明的目的在于根据现有Fluevirosines A研究中未发现其具有抗急性肾衰活性的报道的现状，提供了Fluevirosines A在制备抗急性肾衰药物中的应用。
通过我们的研究发现，Fluevirosines A能够改善急性肾衰时的无尿或少尿症状，保护肾脏的功能。
所述化合物Fluevirosines A,结构如式（Ⅰ）所示：
本发明涉及的Fluevirosines A在制备抗急性肾衰药物中的用途属于首次公开，由于骨架类型属于全新的骨架类型，而且其对于急性肾衰抑制活性强得意想不到，不存在由其他化合物给出任何启示的可能，具备突出的实质性特点，同时用于抗急性肾衰显然具有显著的进步。
具体实施方式
本发明所涉及化合物Fluevirosines A的制备方法参见文献（Hua Zhang，et al.,Fluevirosines A-C:A Biogenesis Inspired Example in the Discovery of New Bioactive Scaffolds from Flueggea virosa.Organic Letters，2013，15（1）：120–123.）
以下通过实施例对本发明作进一步详细的说明，但本发明的保护范围不受具体实施例的任何限制，而是由权利要求加以限定。
实施例1：本发明所涉及化合物Fluevirosines A片剂的制备：
取5克化合物Fluevirosines A,加入糊精料195克，混匀，常规压片制成1000片。
实施例2：本发明所涉及化合物Fluevirosines A胶囊剂的制备：
取5克化合物Fluevirosines A，加入淀粉195克，混匀，装胶囊制成1000粒。
下面通过药效学实验来进一步说明其药物活性。
实验例1 Fluevirosines A对急性肾衰大鼠的治疗作用
（一）实验方法
采用肌肉注射甘油致急性肾功能衰竭大鼠动物模型。选用180～220g健康雄性SD大鼠60只，随机分为5组：假手术组（肌肉注射生理盐水）；模型组（肌肉注射甘油）；Fluevirosines A Ⅰ组（0.3mg/Kg））；Fluevirosines A Ⅱ组（0.6mg/Kg））；Fluevirosines A Ⅲ 组（1.2mg/Kg）），各组大鼠在甘油造模后立即尾静脉注射生理盐水或Fluevirosines A，12和24小时后再给药一次。
（二）观察指标
60只大鼠末次给予Fluevirosines A或生理盐水后放入代谢笼收集24小时尿，留尿后6小时用4%水合氯醛腹腔注射麻醉，采用激光多普勒血流仪测定造模后及治疗后双侧肾脏血流量，取平均值作为单只动物肾血流量；取血制备血清，测定血BUN和Cre；取肾脏，制备10%肾皮质匀浆，测定肾皮质匀浆MDA、GSH、NO（均按试剂盒说明书操作）。
（三）实验结果
1.Fluevirosines A可增加急性肾衰小鼠肾血流量
表1 Fluevirosines A对急性肾衰小鼠肾血流量的影响
*P<0.05与急性肾衰模型组对比
2.Fluevirosines A对急性肾衰小鼠肾功能具保护作用
模型组大鼠较假手术组大鼠24小时尿量显著减少，分别为4.86±0.26ml和11.43±2.53ml；中、高剂量Fluevirosines A组24小时尿量显著高于模型组（P<0.05），三个药物治疗组的尿量具有剂量依赖性，分别为Ⅰ组5.16±0.65ml，Ⅱ组7.93±1.43ml，Ⅲ组9.86±1.39ml。说明Fluevirosines A能改善急性肾衰大鼠的少尿症状。急性肾衰大鼠静脉注射生理盐水24小时后，血清BUN为28.73±1.62mmol/L，Cre为171.63±14.37umol/L，明显高于假手术组，说明模型组动物肾功能损害严重。中、高剂量Fluevirosines A能剂量依赖性地改善急性肾衰大鼠的肾功能（P<0.05）。见表2。
表2 各试验组大鼠肾功能指标比较
*P<0.05与急性肾衰模型组对比
结论：Fluevirosines A能够改善急性肾衰时的无尿或少尿症状，保护肾脏的功能,可以用来制备抗急性肾衰药物。
Claims (1)
1.Fluevirosines A在制备治疗急性肾衰药物中的应用，所述化合物FluevirosinesA结构如式（Ⅰ）所示：
式（Ⅰ）。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310432836.4A CN103446119B (zh) | 2013-09-22 | 2013-09-22 | Fluevirosines A在制备治疗急性肾衰药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310432836.4A CN103446119B (zh) | 2013-09-22 | 2013-09-22 | Fluevirosines A在制备治疗急性肾衰药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103446119A CN103446119A (zh) | 2013-12-18 |
| CN103446119B true CN103446119B (zh) | 2015-07-15 |
Family
ID=49729241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310432836.4A Expired - Fee Related CN103446119B (zh) | 2013-09-22 | 2013-09-22 | Fluevirosines A在制备治疗急性肾衰药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103446119B (zh) |
-
2013
- 2013-09-22 CN CN201310432836.4A patent/CN103446119B/zh not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| Chemical synthesis and biological activities of securinega alkaloids;Wen Zhang;《Journal of Chinese Pharmaceutical Sciences》;20111230;第20卷;全文 * |
| Fluevirosines A-C:A Biogenesis Inspired;Hua Zhang;《ORGANIC LETTERS》;20130130;第15卷(第1期);第121页及123页和表1 * |
| 新型海洋双吲哚类生物碱的研究进展;谷晓辉;《有机化学》;20000228;第20卷(第2期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103446119A (zh) | 2013-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103446119B (zh) | Fluevirosines A在制备治疗急性肾衰药物中的应用 | |
| CN103599102B (zh) | Nitrosporeusines A在治疗急性肾衰药物中的应用 | |
| US8927601B2 (en) | Uses of N-butylidenephthalide in treating a liver injury and improving liver function | |
| CN102872115B (zh) | Houttuynoid A在制备治疗急性肾衰药物中的应用 | |
| CN103356605B (zh) | Chukrasone B在制备治疗急性肾衰药物中的应用 | |
| CN103356646B (zh) | Chukrasone A在制备治疗急性肾衰药物中的应用 | |
| CN103655538B (zh) | Hippolachnin A在治疗急性肾衰药物中的应用 | |
| CN103599105B (zh) | Caesanines D在制备治疗急性肾衰药物中的应用 | |
| JP2019501912A (ja) | 筋肉の保護におけるカンカニクジュヨウ抽出物およびイソアクテオシドの使用 | |
| CN103520172B (zh) | Kadcoccitones A在制备治疗急性肾衰药物中的应用 | |
| CN102861095B (zh) | Houttuynoid E在制备治疗急性肾衰药物中的应用 | |
| CN105456238A (zh) | Norsampsone A在制备治疗急性肾衰药物中的应用 | |
| CN103251637A (zh) | Polyflavanostilbene A在制备治疗急性肾衰药物中的应用 | |
| CN105287529A (zh) | Lycojaponicumins A在制备治疗急性肾衰药物中的应用 | |
| CN105287481A (zh) | Concrescenin A在制备治疗急性肾衰药物中的应用 | |
| CN102872094A (zh) | Houttuynoid B在治疗急性肾衰药物中的应用 | |
| CN105497040A (zh) | Astataricusol A在制备治疗急性肾衰药物中的应用 | |
| CN102872140B (zh) | Houttuynoid C在制备治疗急性肾衰药物中的应用 | |
| CN102861008A (zh) | Aphanamixoid A在治疗急性肾衰药物中的应用 | |
| CN103127151A (zh) | Gypensapogenin A在治疗急性肾衰药物中的应用 | |
| CN103463009A (zh) | Racemosins A在制备治疗急性肾衰药物中的应用 | |
| CN105078954A (zh) | 一种治疗急性肾衰药物及其应用 | |
| CN103462996A (zh) | Neonectrolide A在制备治疗急性肾衰药物中的应用 | |
| CN106389420A (zh) | Ternatusine A在制备治疗急性肾衰药物中的应用 | |
| CN103340850A (zh) | Aphanamgrandiol A在制备治疗急性肾衰药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: GONG JIAN Effective date: 20150602 Owner name: ZHANG LEI Free format text: FORMER OWNER: ZIBO QIDINGLI PATENT INFORMATION CONSULTATION CO., LTD. Effective date: 20150602 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Lei Inventor after: Gong Jian Inventor before: Gao Zhongqing |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: GAO ZHONGQING TO: ZHANG LEI GONG JIAN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150602 Address after: 401, room 2, building 12, building 1, 276000 East Cemetery street, Lanshan District, Linyi, Shandong Applicant after: Zhang Lei Applicant after: Gong Jian Address before: Industrial Park No. 87 Yu Bridge 255086 Shandong province Zibo high tech Zone Wanjie Road Room 301 Applicant before: Zibo Qidingli Patent Information Consulting Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150715 Termination date: 20160922 |